Lonza says contract manufacturing business is recovering
November 2, 2010Manufacturing and Production API, Lonza, contract manufacturing, pharma manufacturing
Lonza said its contract manufacturing business seems to be enjoying a return to form in the third quarter, despite continued …
Pfizer pulls more Lipitor over odour problem
November 2, 2010Manufacturing and Production Lipitor, Lipitor recall, Pfizer, manufacturing compliance, recalls
Pfizer has widened its Lipitor recall after yet another incident in which consumers reported a musty smell emanating from bottles …
Lilly to open diabetes research centre in China
November 2, 2010Research and Development China, Eli Lilly & Co, Lilly Research Laboratories in China, diabetes, lilly
The march of foreign pharma companies into China is to continue with Eli Lilly and Co’s opening of a diabetes …
Nycomed expands China presence with Techpool stake
November 2, 2010Research and Development, Sales and Marketing China, Guangdong Techpool biopharma, Nycomed, emerging markets, emerging pharma markets
Swiss-based Nycomed has acquired a majority stake in Guangdong Techpool biopharma in China, extending its presence in the top tier …
BMS faces approval block unless GMP issues are resolved
November 2, 2010Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing
Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …
Lundbeck UK appoints senior management team
November 2, 2010Research and Development, Sales and Marketing Amanda Badrick, Andy Davis, Andy Jones, Helen Carberry, Lundbeck, Steve Ferguson, appointment, recruitment, research and development, sales and marketing
Lundbeck UK has formed a new senior management team, appointing Steve Ferguson, Andy Davis, Andy Jones, Helen Carberry and Amanda …
Abbott hep C drug ABT-450/r impresses in mid-stage trial
November 2, 2010Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C
Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …
Regulators must catch up with medical science, says FDA
November 2, 2010Research and Development, Sales and Marketing Advancing Regulatory Science, Critical Path Initiative’, Dr Margaret Hamburg, FDA, regulatory affairs
The head of the FDA has declared a need for ‘regulatory science’ to catch up with the advances in medical …
6 tips for regulatory compliance in logistics
November 2, 2010Manufacturing and Production, Research and Development Biocair, GMP, International Council for Harmonisation, pharma logistics, regulatory compliance
Regulation! Regulation! Regulation! Never has our business been more highly regulated than it is today. Seemingly, rules change every day. …
‘Therapeutic clusters’ collaboration launched
November 2, 2010Research and Development ABPI, BIA, Immunology Initiative, Medical Research Council, Office for Strategic Co-ordination of Health and Research, Therapeutic Capability Clusters’, UCB, therapeutic clusters
Two initiatives linking the pharma industry and government-funded research and academia are to go ahead, with the aim of reviving …
Relief as life sciences spared in UK cutbacks
November 1, 2010Research and Development ABPI, Comprehensive Spending Review, Diamond Synchrotron, UK Centre for Medical Research Innovation, UKCMRI, government, science funding
UK government funding for life sciences R&D has been spared from the deep cuts some had feared. Many in the …
FDA approves Novartis’ Afinitor
November 1, 2010Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis
Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …
TranslateMedia ranked 4th in UK Deloitte Technology Fast 50 for 2010
November 1, 2010Business Services
TranslateMedia announced today that it has been ranked 4th in this year’s UK Deloitte Technology Fast 50. The Technology Fast …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
German rebates to cost pharma 1 billion euro
November 1, 2010Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs
The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …
GSK signs rare diseases deal with Amicus
November 1, 2010Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones
GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
Cross-functional marketing leadership
November 1, 2010Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing
Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …
Patent expiries bite into AstraZeneca revenues
October 29, 2010Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel
Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …
MabThera gains maintenance therapy licence
October 29, 2010Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma
Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
Watson submits Crestor copycat
October 28, 2010Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent
Watson Pharmaceuticals is seeking to launch a generic version of AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
